H.C. Wainwright analyst Swayampakula Ramakanth adjusted the firm’s price target on MediWound (MDWD) to $23 from $5.50 and keeps a Buy rating on the shares to account for the reverse split of 1 for 7 shares that became effective on December 20 and the approval of NexoBrid by the FDA on December 29. While awaiting pricing details from Vericel (VCEL) management, Ramakanth currently assumes initial revenue of $6,500 per patient per burn treatment and assumes "meaningful" NexoBrid revenues to start from Q3 of 2023, the analyst noted.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MDWD:
- MediWound price target raised to $25 from $6 at Cowen
- MediWound confirms FDA approval of NexoBrid triggers $7.5M milestone
- MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
- Vericel announces FDA approval of NexoBrid for severe thermal burns
- MediWound NexoBrid U.S. approval came ahead of schedule, says Oppenheimer
